Truncated TDP‐43 proteoforms diagnostic of frontotemporal dementia with TDP‐43 pathology
Alzheimer's & Dementia · 2024-01 · 20 (1) · 103-111
DOI: 10.1002/alz.13368 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 17.07.2023. Verfasst von Lauren M Forgrave und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. Hauptthemen laut MEDLINE: Frontotemporal Dementia, Frontotemporal Lobar Degeneration. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, Canada Foundation for Innovation, British Columbia Knowledge Development Fund.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Biomarkers of TDP‐43 pathology are needed to distinguish frontotemporal lobar degeneration with TDP‐43 pathology (FTLD‐TDP) from phenotypically related disorders. While normal physiological TDP‐43 is not a promising biomarker, low‐resolution techniques have suggested truncated forms of TDP‐43 may be specific to TDP‐43 pathology. To advance biomarker efforts for FTLD‐TDP, we employed a high‐resolution structural technique to characterize TDP‐43 post‐translational modifications in FTLD‐TDP. METHODS High‐resolution mass spectrometry was used to characterize TDP‐43 proteoforms in brain tissue from FTLD‐TDP, non‐TDP‐43 dementias and neuropathologically unaffected cases. Findings were then verified in a larger cohort of FTLD‐TDP and non‐TDP‐43 dementias via targeted quantitative mass spectrometry. RESULTS In the discovery phase, truncated TDP‐43 identified FTLD‐TDP with 85% sensitivity and 100% specificity. The verification phase revealed similar findings, with 83% sensitivity and 89% specificity. DISCUSSION The concentration of truncated TDP‐43 proteoforms—in particular, in vivo generated C‐terminal fragments—have high diagnostic accuracy for FTLD‐TDP. Highlights Discovery: Truncated TDP‐43 differentiates FTLD‐TDP from related dementias. Verification: Truncated TDP‐43 concentration has high accuracy for FTLD‐TDP. TDP‐43 proteoforms
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
- Department of Biochemistry and Molecular Biology and Michael Smith Laboratories, University of British Columbia, Vancouver, Canada.
- Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, Canada.
- Department of Pathology and Laboratory Medicine, St. Paul's Hospital, Providence Health Care, Vancouver, Canada.
ORCID-Profile: Lauren M Forgrave, Leonard J Foster, Mari L DeMarco
Förderung
- CIHR
- Canada Foundation for Innovation
- British Columbia Knowledge Development Fund
- Canadian Institutes of Health Research
Zitieren
APA
Forgrave, L. M., Moon, K. M., Hamden, J. E., Li, Y., Lu, P., Foster, L. J., Mackenzie, I. R. A., & DeMarco, M. L. (2024). Truncated TDP‐43 proteoforms diagnostic of frontotemporal dementia with TDP‐43 pathology. Alzheimer's & Dementia, 20(1), 103-111. https://doi.org/10.1002/alz.13368
Vancouver
Forgrave LM, Moon KM, Hamden JE, Li Y, Lu P, Foster LJ, et al. Truncated TDP‐43 proteoforms diagnostic of frontotemporal dementia with TDP‐43 pathology. Alzheimer's & Dementia. 2024;20(1):103-111. doi:10.1002/alz.13368
BibTeX
@article{Forgrave2024,
author = {Forgrave, Lauren M and Moon, Kyung-Mee and Hamden, Jordan E and Li, Yun and Lu, Phoebe and Foster, Leonard J and Mackenzie, Ian R A and DeMarco, Mari L},
title = {Truncated TDP‐43 proteoforms diagnostic of frontotemporal dementia with TDP‐43 pathology},
journal = {Alzheimer's & Dementia},
year = {2024},
volume = {20},
number = {1},
pages = {103--111},
doi = {10.1002/alz.13368}
}
EUVIMED